bf/NASDAQ:ALXO_icon.jpeg

NASDAQ:ALXO

ALX Oncology Holdings Inc.

  • Stock

0.52

−4.50%

−0.10

USD last updated 13/08 01:59:42

Last Close

0.62

12/08 21:05

Market Cap

352.20M

Beta: 1.66

Volume Today

268.71K

Avg: 271.68K

PE Ratio

−4.46

PFCF: −6.91

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a ran...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -3-2-12019-03-312020-11-122022-05-092023-11-132024-11-112025-08-06

    Revenue (Estimate*)

    1M2M3M4M5M2019-03-312020-11-122022-05-092023-11-132024-11-112025-08-06

    *Estimate based on analyst consensus